Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Demonstrate willingness to participate in the study and comply with its procedures by signing a written informed consent.~* Equal to or greater than 18 years.~* Confirmed chronic hepatitis C with hepatitis C virus (HCV) RNA positive in plasma.~* No previous use of PegIntron Pen.~Exclusion Criteria:~* Hypersensitivity to the active substance or to any interferon or to any of the excipients.~* Pregnant women.~* Women who are breastfeeding.~* Existence of or a history of severe psychiatric condition, particularly severe depression, suicidal ideation or suicide attempt.~* A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease in the previous six months.~* Severe debilitating medical condition, including patients with chronic renal failure or creatinine clearance \< 50 ml/minute.~* Auto immune hepatitis or a history of autoimmune disease.~* Severe hepatic dysfunction or decompensated cirrhosis of the liver.~* Pre-existing thyroid disease unless it can be controlled with conventional treatment.~* Epilepsy and/or compromised central nervous system (CNS) function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genotype 1 CHC Participants (Type: None): None
- Non-genotype 1 CHC participants (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).